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Neoantigens (nAgs) are promising tumor antigens for cancer vaccination with the potential
of inducing robust and selective T cell responses. Genetic vaccines based on Adenoviruses
derived from non-human Great Apes (GAd) elicit strong and effective T cell-mediated
immunity in humans. Here, we investigate for the first time the potency and efficacy of a
novel GAd encoding multiple neoantigens. Prophylactic or early therapeutic vaccination with
GAd efficiently control tumor growth in mice. In contrast, combination of the vaccine with
checkpoint inhibitors is required to eradicate large tumors. Gene expression profile of tumors
in regression shows abundance of activated tumor infiltrating T cells with a more diversified
TCR repertoire in animals treated with GAd and anti-PD1 compared to anti-PD1. Data suggest
that effectiveness of vaccination in the presence of high tumor burden correlates with the
breadth of nAgs-specific T cells and requires concomitant reversal of tumor suppression by
checkpoint blockade.
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Therapeutic efficacy of cancer vaccination depends on sev-eral factors, including: (i) the selection of the mostappropriate target tumor antigens (ii) the ability to coun-
teract the immune-suppressive tumor microenvironment, and
(iii) the efficiency of the vaccination platform at inducing robust
cellular immunity.
Regarding the antigen choice, neoantigens (nAgs) are emerging
as an attractive target for cancer vaccines. nAgs are expressed in
tumor cells as a result of mutations occurring in coding genes.
They are non-self-peptides, without pre-existing central tolerance,
with the potential of inducing strong immunogenicity and effec-
tive antitumor activity compared with classical tumor-associated
antigens represented by overexpressed self-proteins1,2. As nAgs
are unique to cancer cells, the risk of inducing autoimmunity is
very low, qualifying them as safe immunogens with low risk of
damaging normal healthy tissues. Evidence on the relevance of
nAgs for the success of immunotherapy comes from the striking
correlation found between tumor mutational burden and the
efficacy of checkpoint blockade (CPB)3,4.
Moreover, preclinical studies showed effectiveness of nAgs
cancer vaccination in several models, prompting initiation of
clinical testing of nAgs-based vaccines by means of different
approaches, including peptides and RNA5–7. Results from phase-I
clinical studies showed a good safety profile and induction of
immune responses, mainly CD4+ T cells, against some nAgs8–10.
Cancer cells promote their survival by limiting host immune
response through several mechanisms. PD1/PDL1 interaction has
been shown to have a key role in the impairment of anticancer
T-cell immunity11,12. Therapeutic treatment with antibodies
blocking the interaction between PD1 and PDL1 results in clinical
benefit due to their ability to reverse the “exhausted” phenotype
of spontaneously induced antitumor T cells13–17. Despite their
success in many advanced malignancies, PD1/PDL1 blockade is
efficacious only in a minority of treated patients18. nAgs-based
vaccination is expected to synergize with CPB or other immu-
nomodulatory drugs, able to revert tumor-induced immunosup-
pression, by increasing the breadth and potency of nAgs-specific
T cells.
A paradigm for an efficient induction of cytotoxic T cells is that
the antigen is expressed from within the cells. This requirement
makes viral vectored vaccines one of the preferred technologies
for the induction of effective antitumor immunity. Adenoviruses
have been shown to be a powerful genetic vaccine platform. In
particular, non-human Great Apes-derived Adenoviruses (GAd)
represent an optimal choice with respect to the widely used
human Adenovirus 5 (hAd5) because they can overcome the issue
of anti-Ad5 pre-existing immunity present in humans that
negatively affects its potency as a vaccine vector19. Indeed, a large
number of clinical studies have shown potent immunogenicity
and very good safety and tolerability of GAd vectors derived from
different species (i.e., Chimpanzees and Bonobos)20–25.
One unique feature of the GAd platform is the ability to encode
for large antigens (ie, over 2000 amino acids), as for a candidate
HCV vaccine in phase 2 of clinical development23. Moreover,
GAd-encoding artificial antigens generated by joining several
fragments from different proteins led to unprecedented T-cell
responses in humans26. These characteristics make GAd vectors
particularly suitable to encode large artificial antigens composed
of strings of nAgs peptides derived from patient-specific tumor
mutations. In this study, to validate GAd as an effective and novel
neoantigen-based cancer vaccine, we have measured the anti-
tumor activity in several settings of low and high tumor burden.
We demonstrate that effective antitumor response in the presence
of high tumor burden requires concomitant treatment of GAd
vaccine with immunomodulatory molecules able to counteract
the immune-suppressive tumor microenvironment, such as
anti-PD1 or anti-PDL1 antibodies. The contribution of the vac-
cine to the CPB therapy analyzed by transcriptomic analysis
demonstrates diversification of the intratumoral T-cell repertoire
in animals treated with GAd vaccine and anti-PD1. The trans-
lational relevance of our results is supported by the observation
that mice responding to the treatments show upregulation of
genes linked to T-cell activation and effector functions, including
those belonging to a tumor inflammation signature (TIS) found
in patients responding to anti-PD1 immunotherapy27,28.
Results
GAd induces potent neoantigen-specific T-cell responses. We
selected the murine colon carcinoma CT26 cell line because of its
high nAgs load and responsiveness to anti-PD1 therapy29,30.
CT26 were injected subcutaneously in mice and, once the tumors
developed, they were harvested and processed for DNA and RNA
sequencing by next-generation sequencing (NGS). Candidate
nAgs were selected from the identified mutations based on: (i)
MHC-I and II predictions of binding affinity31, (ii) mutation
allele frequency in tumor DNA, and (iii) mRNA expression.
Thirty-one single-nucleotide variant (SNV) mutations were
prioritized based on the sequential use of specific cut-off values
for each of the three parameters (Fig. 1a and Table 1). Each
amino acid (aa) change determined by a SNV was flanked
upstream and downstream by 12 wild-type aa for a total length of
25 aa in order to generate a nAg containing the maximum
number of potential CD4+ and/or CD8+ T-cell epitopes. The 31
nAgs selected by this process were joined head to tail to generate
a single artificial protein and the corresponding gene was cloned
in a GAd vector (GAd-CT26-31), taking advantage of its large
cloning capacity. Single injection of the vector induced potent
T-cell immunity in naive mice as measured by ex vivo IFN-γ
ELISpot. Seven out of 31 predicted neoantigens were able to elicit
a detectable immune response (Fig. 1b), with induction of robust
CD8+ and CD4+ T-cell responses measured on the pool of 31
peptides encoded by the vaccine (Fig. 1c). The quality of T-cell
responses induced by individual nAgs was determined by intra-
cellular cytokine staining (ICS) and fluorescence-activated cell
sorting (FACS) analyses for six out of seven immunogenic nAgs.
Three nAgs induced CD4+ T cells and three were able to induce
CD8+ T-cell responses (Supplementary Fig. 1), showing induc-
tion of a well-balanced CTL response. Notably, cross-reactive
T-cell responses against the corresponding wild-type peptides
were not detected (Supplementary Fig. 2a).
Early vaccination with GAd controls tumor growth. To inves-
tigate the effectiveness of our GAd nAgs-based vaccine in vivo, we
tested its antitumor effect in the following early versus late vac-
cination settings: (1) prophylactic setting; (2) early intervention in
a lung metastases model; (3) advanced therapeutic setting in large
established subcutaneous tumors. In the first model, mice were
first immunized with GAd-CT26-31 and subsequently challenged
with CT26 tumor cells to evaluate the preventative value of the
vaccination. This prophylactic intervention led to protection in
100% of vaccinated mice, whereas all untreated mice developed
large tumors (Fig. 2a). Mice immunized with the same dose of a
GAd vector encoding an unrelated antigen were indistinguishable
from untreated mice (Supplementary Fig. 3). Similarly, GAd-
CT26-31 was highly effective in eradicating lung metastases of
CT26 cells in an early therapeutic setting, in which the vaccina-
tion was performed 3 days after intravenous injection of tumor
cells (Fig. 2b).
We also generated a GAd vector (GAd-CT26-5) encoding the
very same five CT26 nAgs previously published7, and we
measured immunogenicity and efficacy in prophylactic and early
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treatment settings. Three of the five previously identified CT26
neoantigens (#5, #18, and #28) were found immunogenic post
vaccination with GAd-CT26-5 (Supplementary Table 1 and
Supplementary Fig. 4a). Interestingly, those three nAgs were also
selected by our pipeline for inclusion in the longer GAd-CT26-31
construct. Vaccination with GAd-CT26-5 had also a potent
antitumor activity in 100% of treated mice in both prophylactic
and early treatment settings (Supplementary Fig. 4b–c).
Despite the efficacy observed in the prophylactic and early
vaccination treatments, no antitumor activity was observed in
mice bearing large established subcutaneous tumors vaccinated
with either the GAd-CT26-31 (Fig. 2c) or the GAd-CT26-5 vector
(Supplementary Fig. 4d).
To gain insights into the mechanism of tumor resistance, we
measured vaccine-induced nAgs-specific T-cell responses in mice
bearing large tumors. Despite the lack of efficacy in this setting,
vaccine-induced nAgs-specific T cells were recovered from tumor
infiltrates 10 days post vaccination and their effector function was
measured ex vivo after re-stimulation with cognate nAgs peptides
showing an effective production of IFN-γ by ICS assay (Fig. 2d).
We also investigated the presence of spontaneous immune
response against a previously described CD8+ T-cell epitope,
gp70-AH1, derived from endogenous murine leukemia virus
present in CT26 cells32. CD8+ T cells against gp70-AH1 were
detected in untreated and vaccinated mice at similar levels
(Supplementary Fig. 5). Thus, both spontaneous and vaccine-
induced T cells can infiltrate tumors but cannot control growth of
established tumors.
Treatment of large tumors requires combination therapy. To
improve the effectiveness of GAd vaccine in mice with high
tumor burden, the combined treatment of GAd and anti-PD1 was
evaluated. Anti-PD1 was chosen as it represents the most widely
used CPB and it is approved for many cancer indications. CT26
established tumors responded to anti-PD1 monotherapy in a
small fraction of treated animals (15%), by showing complete
regression of tumors. Combined treatment of anti-PD1 and GAd-
CT26-31 provided remarkable tumor control, causing complete
tumor regression in ~50% of mice (Fig. 3a). Surprisingly, com-
bination of GAd-CT26-5 vaccine with anti-PD1 did not improve
the cure rate of anti-PD1 alone (Supplementary Fig. 4d).
Animals cured by the combination of GAd-CT26-31 and anti-
PD1 showed the induction of a systemic CD4+ and CD8+ T-cell
response comparable to that obtained in naïve mice both in terms
of breadth and potency (Fig. 3b). Comparison of nAgs-specific
T-cell responses in responder versus non-responder mice showed
significantly higher levels of IFNγ+ CD8+ T cells in the
responder group (Fig. 3c). Low levels of a spontaneous immune
response against only one of the 31 tested nAgs (nAg#4) was
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Fig. 1 In vivo immunogenicity of GAd encoding CT26 neoantigens. a Schematic of the approach used to identify CT26 tumor specific mutations and
generation of the vaccine; analysis of non-synonymous single nucleotide variants on DNA and RNA NGS allowed the selection of 31 nAgs, which were
prioritized according to (i) MHC class I (predicted IC50≤ 500 nM) and II (binding score ≤ 1) binding predictions, (ii) tumor allele frequency (MAF≥ 25%),
and (iii) RNA expression (≥1 mutated RNA read). Selected nAgs were cloned in tandem in a GAd vector and tested in vivo. b In vivo immunogenicity of
GAd-CT26-31. T-cell responses were measured by IFN-γ ELISpot on splenocytes of naive mice 3 weeks post immunization with 5 × 108vp of GAd-CT26-31
(n= 10–30 mice/group). Responses against individual nAgs peptides found immunogenic are shown; nAgs ID is in red for nAgs inducing CD8+ T-cell
responses or in blue for nAgs inducing CD4+ T-cell responses. Peptide diluent DMSO and Concanavalin A were used as negative and positive control,
respectively. Data are representative of three independent experiments. c The quality of induced T-cell responses (CD4, blue circles, and CD8, red
squares) was assessed by IFN-γ ICS by using a pool of 31 nAgs peptides (POOL 31) (n= 6 mice/group, representative of three experiments). Peptide
diluent DMSO and PMA/Ionomycin were used as negative and positive control, respectively. SFC= Spot forming cells, ConA=Concanavalin A
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found in animals responding to anti-PD1 treatment alone
(Supplementary Fig. 6). Mice that became tumor free after the
combined treatment were all protected from a second CT26
tumor challenge, demonstrating effective induction of memory
T cells (Fig. 3d). Selective depletion of CD8+ T cells completely
abrogated the antitumor effect, highlighting the contribution of
this lymphocyte population to the treatment efficacy. In contrast,
depletion of CD4+ T cells did not impact efficacy of the treatment
(Fig. 3e). The key role of CD8+ T cells was also confirmed in the
early therapeutic setting of lung metastases (Fig. 3f).
Activation of an immune gene signature in responder tumors.
To identify functional pathways associated with treatment
response or resistance, tumors were collected 17 days from the
start of the treatment, when it was possible to discriminate
between those in progression (non-responders) from those in
regression (responders). DNA and RNA were extracted from
tumors of mice belonging to the three treated groups: (i) vaccine
alone, (ii) anti-PD1 alone,(iii) combination of anti-PD1 and
vaccine and from untreated animals. DNA-exome sequencing
and RNASeq on tumors harvested from mice that failed to
respond to combined treatment showed that all immunogenic
mutations were still present and expressed in non-responders,
indicating that lack of response to treatment in those animals was
not due to nAgs loss (Supplementary Table 2). Resistance to
treatment was not associated with genetic loss of MHC-I or lack
of MHC expression (Supplementary Table 3).
Gene expression profiles were also evaluated. Transcriptional
profiles of tumors from non-responders in the anti-PD1, vaccine
alone, or combination groups were all indistinguishable from
those of untreated tumors, consistent with the lack of tumor
shrinkage. However, when we compared gene expression of
responders, both from anti-PD1 and combination groups, versus
untreated tumors, significantly differentially expressed genes
(DEG) were observed in tumors from regressors. Although in
responder mice treated with combination therapy there were
1353 upregulated and 59 downregulated genes, only 413 genes
were upregulated and two downregulated in responder mice
treated with anti-PD1 alone (Fig. 4a and Supplementary Data 1),
most of whom were shared with the combination group (Fig. 4b).
The remaining genes, uniquely upregulated in the combination
group, also showed a trend toward induction in mice receiving
anti-PD1 only (Fig. 4c), and even the common DEG were more
significantly upregulated in the combination group.
Of note, tumors responding to the combination upregulated 15
out of 18 genes belonging to the TIS previously identified in
patients responding to anti-PD1 (Supplementary Fig. 7)27,28.
Gene ontology (GO) enrichment analysis of the 1412 DEG
revealed significant changes in pathways related to the immune
response. Figure 4d shows biological processes for which at least
the 40% of genes were significantly upregulated in combo treated
animals. Most of these pathways belong to innate and adaptive
immunity activation. Interestingly, five of these biological
processes, including regulation of TCR signaling, T-cell activation
and interferon gamma production, showed a significant
Table 1 CT26 neoantigens encoded by GAd-CT26-31 vaccine
ID Gene Neoantigen sequence RNA reads
(mut/wt)
MAF (%) MHC-I IC50 MHC-II score
1 Phf3 PGPQNFPPQNMF[G/E]FPPHLSPPLLPP 6/10 57 41.5 48.7
2 Zeb1 GAQEEPQVEPLD[L/F]SLPKQQGELLER 8/1 36 121.0 47.5
3 Trappc12 AVFAGSDDPFAT[A/P]LSMSEMDRRNDA 5/21 26 457.9 12.7
4 Aldh18a1 HSGQNHLKEMAI[P/S]VLEARACAAAGQ 12/7 51 13035.9 0.05
5 E2f8 ILPQAPSGPSYA[I/T]YLQPAQAQMLTP 3/5 32 320.5 6.8
6 Gid8 MSYAEK[P/S]DEITKDEWMEKL 7/31 26 67.0 49.8
7 Hdac2 GAGKGKYYAVNF[P/S]MRDGIDDESYGQ 29/30 40 39.48 40.5
8 Ttl YRGADKLCRKAS[L/S]VKLVKTSPELSE 4/8 46 4768.9 0.2
9 Haus6 DSNLQARLTSYE[A/T]LKKSLSKIREES 29/9 33 18.2 7.49
10 Ndc1 HSFIHAAMGMAV[A/T]WCAAIMTKGQYS 3/1 70 15203.7 0.84
11 Glud1 LRTAAYVNAIEK[V/I]FKVYNEAGVTFT 353/89 68 141.15 9.4
12 G2e3 FEGSLAKNLSLN[S/F]QAVKENLYYEVG 12/15 53 467.9 21.1
13 Cad DPRAAYFRQAEN[G/D]MYIRMALLATVL 11/3 52 2660.3 0.7
14 Dars2 LRSQMVMKMREY[L/F]CNLHGFVDIETP 6/7 46 3795.6 0.39
15 Smarcd1 DLLAFERKLDQT[I/V]MRKRLDIQEALK 16/2 46 11015.8 0.99
16 Zfp955b IKREKCWKD[V/A]TY[S/P]ESFHTLESVPAT 2/16 45 271.8 9.2
17 Rwdd2b GRSSQVYFTINV[S/N]LDLSEAAVVTFS 2/9 45 143.0 8.6
18 Slc20a1 KPLRRNNSYTSY[T/I]MAICGMPLDSFR 50/47 42 118.0 3.5
19 Ddx27 TTCLAVGGLDVK[S/F]QEAALRAAPDIL 13/16 41 8042.7 0.6
20 Top3a IYEFDYHLYGQN[V/I]TMIMTSVSGHLL 1/1 41 124.9 11.4
21 Slc41a2 PDSFSIPYLTAL[G/D]DLLGTALLALSF 2/5 40 134.8 24.5
22 Ttc39a YATILEMQAMMT[F/L]DPQDILLAGNMM 8/0 37 4108.0 0.2
23 Mtch1 SWIHCWKYLSVQ[G/S]SQLFRGSSLLFRR 160/226 36 13.46 2.2
24 Suv39h2 YDNKGITYLFDL[D/Y]YESDEFTVDAAR 2/7 36 344.48 33.6
25 Tomm70a AQAAKNKGNKYF[K/Q]AGKYEQAIQCYT 17/41 35 459.4 5.2
26 Csnk2b QPMLPIGLSDIP[G/D]EAMVKLYCPKCM 79/146 34 202.2 11.8
27 Caprin2 HRGAIYGSSWKY[S/F]TFSGYLLYQD 1/1 31 36.8 50.7
28 Dhx35 VIQTSKYYMRDV[T/I]AIESAWLLELAP 5/11 29 67.5 0.7
29 Xpot PRGVDLYLRILM[A/P]IDSELVDRDVVH 17/53 28 41.5 4.7
30 Dclre1c QIEQDALCPQDT[H/Y]CDLKSRAEVNGA 6/6 40 69.1 26.3
31 Noc3l ALASAILSDPES[H/Y]IKKLKELRSMLM 5/3 60 101.2 10.7
List of CT26 neoantigens encoded by GAd-CT26-31 vaccine. nAgs were selected according to (i) MHC class I (predicted IC50≤ 500 nM) and MHC class II (binding score ≤1) binding predictions, (ii)
tumor allele frequency (MAF≥ 25%), and (iii) RNA expression (≥1 mutated RNA read). The mutated amino acid is underlined. Predicted binders to MHC-I and II are highlighted in bold. MAF=minor
allele frequency
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enrichment in the number of genes specifically modulated by the
combination treatment compared to anti-PD1 (Fig. 4d and
Supplementary Data 2).
Combined therapy diversifies intratumoral TCR repertoire.
TCR representation was analyzed from RNA-sequencing data of
tumors as previously described33. As we determined an increased
breadth of immune response by IFN-γ ELISpot analysis in mice
cured by the combination of GAd-CT26-31 and anti-PD1, we
interrogated the transcriptome to evaluate if there were changes
in the number of TCR clonotypes in the different treatment
groups. The combination treatment indeed resulted in diversifi-
cation of the intratumoral T-cell repertoire, detected as unique
TCR-beta CDR3 sequences. A significant increase of the total
number of TCR-beta clonotypes was observed by comparing the
combination versus the anti-PD1 monotherapy treatment
(Fig. 5a), reflecting a larger T-cell diversity in the former treat-
ment group. Vaccination per se did not result in such enrichment
of different clonotypes within the tumor, suggesting lack of
expansion of vaccine-induced T cells in the absence of anti-PD1
treatment. A clear difference between responders and non-
responders to the combined treatment was found evaluating the
TCR-beta CDR3 equality distribution (evenness). Responders to
the combination showed lower evenness corresponding to a TCR
repertoire dominated by specific T-cell clones. A similar trend,
although not significant, was also observed between responders
and non-responders to anti-PD1 therapy. This indicates that
intratumoral expansion of selected T-cell clones correlates with
the response (Fig. 5b).
Synergy of GAd and CPB is confirmed in a second model. The
synergy between GAd nAgs-based vaccine and CPB was inves-
tigated in the MC38 cell line derived from C57BL/6 murine colon
adenocarcinoma. For these experiments, we used seven nAgs
previously identified in MC38 cells by mass spectrometry analysis
and shown to be able to induce CD8+ T-cell responses (Table 2)5.
All seven mutations were confirmed to be present in tumors of
subcutaneously injected mice by exome sequencing (Supple-
mentary Table 4). Each aa change determined by the mutation
was flanked upstream and downstream by wild-type aa to gen-
erate the nAgs, as described previously for the CT26 nAgs. The
seven nAgs were joined head to tail to generate an artificial
protein, which was encoded into the GAd vector. A single GAd
vaccination of naive mice induced T cells response against six out
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of seven nAgs (Fig. 6a). All T-cell responses were confirmed to be
CD8+ by ICS (Supplementary Fig. 8). Importantly, no cross-
reactive T-cell responses were detected against the wild-type
sequence post vaccination (Supplementary Fig. 2b). Vaccine
efficacy was evaluated in animals bearing large MC38 tumors.
Vaccination was confirmed to be ineffective as a stand-alone
treatment, whereas CPB monotherapy induced regression of
established tumors only in a minority of animals (7% anti-PD1;
9% anti-PDL1). In contrast, synergistic activity was demonstrated
when the vaccine was combined with either anti-PD1 or
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ns
ns
ns
2000
1500
1000
Tu
m
o
r 
vo
lu
m
e 
(m
m3
)
SF
C/
10
6  
sp
le
no
cy
te
s 
500
400
200
0
2000
1500
1000
Tu
m
o
r 
vo
lu
m
e 
(m
m3
)
500
400
200
0
0 4 7 12 14 18 20 26 0 4 7 12 14 18 20 26 0 4 7 12 14 18 20 26
Days
2000
1500
1000
500
400
200
0
2000 150
100
50
0
– – αCD4 αCD8
1500
1000
500
400
200
0
1
10
0.1
0.01
Responder
Undepleted CD4 depleted CD8 depleted
Lu
ng
 n
od
ul
es
 n
u
m
be
r
Non-responder
2000
1200
1000
800
600
400
200
25
0
1500
1000
500
400
200
0
0 3 6 10 13
CD8
CD4
17 20 24 30 0 3 6 10 13 17 20 24
Days
neoAg ID 4 5 10 11 18 23 2830
GAd-CT26-31 + α-PD1
GAd-CT26-31 + α-PD1
GAd-CT26-31 + α-PD1 Early therapeutic metastatic
Days post re-challenge
0
25
50
75
100
Control
GAd + α -PD1
0 20 40 60 80 100
O
ve
ra
ll 
su
rv
iva
l (%
)
GAd-CT26-31Ctrl
%
 IF
N 
γ +
 C
D8
 o
r C
D4
GAd-CT26-31 + α-PD1
a
c d
b
e f
Fig. 3 Efficacy of GAd in animals with high tumor burden requires the combination with anti-PD1. aMice (n= 20/group) were inoculated s.c. with CT26 cells.
One week later, animals were randomized according to tumor volume and treated with anti-PD1 alone (left panel) or in combination with GAd-CT26-31 (right
panel). Vaccine was administered at day 0 (i.m.), whereas anti-PD1 was given twice per week until day 16 (i.p.). Tumor growth over time is shown for
individual mice. Red and blue curves represent non-responder mice, black curves indicate responder mice. Data are from three independent experiments (two-
tailed Chi-Square test; *p < 0.05). b Analysis of nAg-specific T-cell responses quantified by IFN-γ ELISpot in responder mice (splenocytes) cured by the
combination of GAd and anti-PD1. Responses against the immunogenic nAgs are shown (n= 6–9 mice per group, representative of two independent
experiments). c nAg-specific T-cell responses measured by IFN-γ ICS in responder and non-responder mice treated with GAd-CT26-31 and anti-PD1.
Percentages of IFN-γ+ CD4+ and CD8+ T cells measured at day 30 upon peptides pool re-stimulation are shown. (two-tailed Mann–Whitney U test; **p <
0.01, n.s., not significant). d Tumor-free mice treated with anti-PD1 and GAd-CT26-31 were challenged with a second CT26 tumor inoculum (n= 10, at least
three independent experiments). Animals survival after second challenge was monitored until 100 days post re-challenge. (Log-rank test; ***p < 0.001).
e Tumor growth in tumor bearing mice treated with GAd-CT26-31 and anti-PD1 and depleted for CD4+ or CD8+ T cells. Data represent at least two
independent experiments. (Fisher exact test; *p < 0.05). f Number of lung nodules measured in control mice or mice vaccinated with GAd-CT26-31 (n= 8 per
group from one experiment) and depleted for CD4+ or CD8+ T cells (two-tailed Mann–Whitney U test; **p < 0.01; n.s., not significant)
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anti-PDL1 antibodies with shrinkage of tumors observed in
~ 30% of mice (Fig. 6b, c).
Discussion
Therapeutic cancer vaccines targeting unique patients’ specific
mutations are a promising approach to improve the efficacy of
CPB therapy by increasing the breadth and potency of nAg-
specific T cells. One of the main challenges for the development
of therapeutic vaccines is the availability of a delivery system
capable of safe and efficient induction of T-cell immunity. Non-
human Great Apes Adenoviruses have recently emerged as a safe
and powerful genetic vaccine platform in humans. This class
of replication-defective adenoviral vectors was tested in over
four thousand humans of all ages, showing induction of
unprecedented CD8+ and CD4+ T-cell responses and a good
safety profile20,26,34.
Here, we investigated for the first time the efficacy of GAd
vaccines encoding tumor nAgs. A GAd encoding 31 nAgs (GAd-
31), the largest number used so far for nAg-based vaccines,
selected from the murine CT26 colon carcinoma cell line, was
capable of inducing potent T-cell immunity, with overall >1000
antigen-specific IFN-γ secreting lymphocytes/million splenocytes
and the induction of both CD8+ and CD4+ T lymphocytes. Only
a fraction (20%) of predicted nAgs was found to be immunogenic,
in line with previously published reports35, underlying the cur-
rent limitations of the neoantigen prediction methods36. Indeed,
no single method available today allows for a reliable identifica-
tion of the immunogenic/efficacious neoantigens, making their
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empirical determination still not feasible in the clinical setting of
personalized vaccination. In this scenario, one of the advantages
of the GAd vector technology is its ability to accommodate large
gene inserts, allowing the targeting of many neoantigens.
Therefore, the use of this platform offers the opportunity to
overcome the limits of the prediction algorithms. Of note, the 31
nAgs used here do not represent the upper limit of the GAd
vectors, as we recently managed to successfully express over 60
nAgs in a single vector (unpublished).
Previous nAgs-based cancer vaccination studies in mice have
shown that significant efficacy can be achieved in a model of lung
metastases by administering synthetic RNA vaccine encoding five
neoantigens, soon after intravenous injection of CT26 tumor
cells7. To bridge our results with these previously published data,
we encoded in GAd the very same set of five nAgs (GAd-5) and
observed comparable efficacy in this early therapeutic setting with
our GAd-31 vector. However, vaccination with either GAd alone
was not capable to reduce disease progression when administered
to mice with large established tumors. This lack of efficacy was
not owing to an impaired induction of nAgs-specific immune
response or inefficient lymphocyte trafficking to the tumor, as
GAd vaccine-induced T cells were detected in the tumor post
vaccination. Nevertheless, these responses failed to control tumor
growth. Transcriptome analysis on tumors harvested 17 days post
vaccination from GAd vaccinated and untreated animals did not
reveal differences between the two groups either in gene expres-
sion profiles or in the number of unique TCR clones present in
the tumor, suggesting lack of expansion of vaccine-induced
T cells.
Treatment of established tumors with anti-PD1 was able to
induce regression in a limited number of mice (15%). Co-
treatment with the shorter GAd encoding five previously identi-
fied CT26 nAgs7 did not change the rate of response. In contrast,
combined treatment with the GAd-31 vaccine consistently
resulted in a three-fold increase in the number of mice showing
complete regression (~ 50%), correlating with increased number
of T-cell clones with unique TCR in this stringent setting of high
tumor burden. Of note, the GAd-5 shorter construct shared only
three immunogenic nAgs with the long GAd-31. Although we did
not directly explore whether the difference between the two
vaccines is owing to quality or quantity of the encoded neoanti-
gens, our results suggest that the ability to design multi-epitope
vaccines may allow to overcome the limits imposed by the
inaccuracy of the bioinformatics tools currently available to
predict truly immunogenic nAgs.
The antitumor effect of the vaccination was found to be
dependent on CD8+ T cells in both early and late treatments
setting, whereas other studies have shown that vaccination with a
single CT26 nAg inducing CD4+ T-cell responses reduced the
formation of metastases in an early therapeutic setting37. Likely,
both components of adaptive immune response can play a role at
different stages of tumor formation, and the ability of balanced
induction of both CD4+ and CD8+ T cells is an advantageous
feature of the GAd vaccination platform.
Despite a significant improvement over mono-therapies, the
combined regimen failed to cure about half of the treated mice.
Of note, tumor escape was not associated to immunoselection of
tumor variants lacking expression of the targeted nAgs. Eluci-
dating the bases for resistance will allow to identify targetable
mechanisms to improve the therapeutic efficacy of nAgs vacci-
nation. Tumors in regression after the combined treatments
showed upregulation of transcriptional networks linked to T cells
activation and effector functions, including 15 out of 18 genes
belonging to a TIS described in patients who responded to anti-
PD1 immunotherapy28. Consistent with immune recognition of
the tumor, highly expressed genes included immune-related
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Table 2 MC38 neoantigens encoded by GAd-MC38-7 vaccine
ID Gene symbol Gene ID Neoantigen sequence
1 CPNE1 266692 DFTGSNGDPSSP[D/Y]SLHYLSPTGVNEY
2 IRGQ 210146 KARDETAALLNSA[G/V]LGAAPLFVPPAD
3 AATF 56321 SKLLSFMAPIDHT[A/T]MSDDARTELFRS
4 REPS1 19707 GRVLELFRAAQL[P/A]NDVVLQIMELCGATR
5 MED12 59024 DIDPSSSVLFE[D/Y]MEKPDFSLFSP
6 DPAGT1 13478 EAGQSLVISASIIVFNL[V/L]ELEGDYR
7 ADPGK 72141 GIPVHLELASMTN[R/M]ELMSSIVHQQVFPT
List of the MC38 neoantigens encoded by GAd-MC38-7 vaccine. The mutated amino acid is in bold next to the wild-type amino acid
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genes, such as Granzyme B/K associated with cytolytic function,
T-cell markers (CD2, CD3D, CD3E, IL2RG), chemokines/che-
moattractants (CXCL9, CXCR6, CXCL10), genes involved in
antigen presentation (CIITA, H2-T23, and H2-EA-PS) and
immunomodulatory molecules such as IDO and LAG3, the last
two factors likely being upregulated as a consequence of T-cell
activation and IFN-γ signaling to restrain the antitumor immune
responses. The pattern of genes modulated in response to com-
bination therapy was also found in anti-PD1 responders, with a
global trend towards a more pronounced activation in the com-
bination group, reflecting a partially common effect on immune
cells. However, a more-striking difference between the combi-
nation and anti-PD1 therapy was found when analyzing the TCR
repertoire. Concomitant treatment with GAd vaccine and anti-
PD1 increased the TCR diversity, suggesting the broadening of
tumor-reactive T cells. Moreover, selective expansion of specific
subsets of T-cell clones was found to be associated with efficacy in
the combination group, suggesting that the growth of specific
immunologically relevant T-cell populations is a key feature for
the antitumor activity. The skewing of specific T-cell clonotypes
has also been reported in patients responding to immunother-
apy38, underlying the translational relevance of our observations.
The robustness of our observation was confirmed in a second
model by using a GAd vector encoding seven nAgs previously
identified in murine MC38 tumor cells by mass spectrometry5.
Administration of the MC38 GAd vaccine induced potent T-cell
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responses, with overall >4000 antigen-specific IFN-γ-secreting
lymphocytes/million splenocytes, and with six out of seven
encoded nAgs being immunogenic. Notably, previous studies
using the same nAgs administered as a mixture of synthetic
peptides in adjuvants showed that only three out of seven nAgs
induced a T-cell response5. Moreover, synergy of vaccination with
both anti-PD1 or anti-PDL1 treatment was shown in this model
by treating animals with large tumors.
GAd vectors represent a novel class of safe, potent, and clini-
cally validated genetic vaccine, which can be manufactured
according to a standardized, reliable, and highly reproducible
process that is independent from the size and the identity of the
encoded antigen. A major obstacle to developing personalized
vaccines based on individual nAgs is whether they can be pro-
duced in a timeframe that will allow for their administration to
patients with advanced tumors. To this end, we have developed a
fast process for the assembly of gene strings encoding over 60
unique patient mutanome-specific neoantigens and for the pro-
duction of personalized GAd vaccines within 6 weeks from the
time of patient biopsy for rapid administration to cancer patients.
Methods
Mice. Six-week-old female BALB/c or C57BL/6 mice were purchased from Envigo.
All day-to-day care was performed by trained mouse house staff at Plaisant, Castel
Romano. All experimental procedures were approved by the Italian Ministry of
Health (Authorizations 213/2016 PR) and have been done in accordance with the
applicable Italian laws (D.L.vo 26/14 and following amendments), the Institutional
Animal Care and ethic Committee of CEINGE and Allevamenti Plaisant SRL.
Cell culture. CT26 (BALB/c mouse undifferentiated colon carcinoma) and MC38
(C57BL/6 mouse colon adenocarcinoma) were purchased from ATCC. Cell lines
were cultured in complete RPMI-1640 or Dulbecco's Modified Eagle medium,
respectively, supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 1%
(v/v) penicillin/streptomycin and maintained at 37 °C in 5% CO2. They were not
further authenticated but cultured for a limited number of passages. Cell lines were
tested for the absence of mycoplasma contamination by PCR.
Adenoviral vectors production. The coding sequences for CT26-5 and MC38-7
transgenes were purchased as phosphorylated gBlock dsDNA fragments (IDT) and
cloned into p-tetOCMV-BGHpA, containg CMV promoter with two TetO repeats
and a BGH polyA, previously digested with EcoRV (New England Biolabs). The
CDS for CT26-31 was generated by Gibson assembly (New England Biolabs) of two
overlapping gBlock sequences (Integrated DNA Technologies) into p-tetOCMV-
BGHpA previously digested with EcoRV and Not1 restriction enzymes (New
England Biolabs). The expression cassettes were then transferred into pGAd
plasmid, containing the E1/E3/E4 deleted in which the E4 is replaced with Ad5 E4
ORF6 of a Great Ape Adenovirus (serotype group C). The transgene cassette was
introduced into the E1 deletion by homologous recombination in BJ5183 cells
(Agilent). GAds vectors were then produced by transfection of adherent M9 cells
(293 cells derivative) with Lipofectamine 2000 (Invitrogen, Thermo Fisher Scien-
tific) and amplification in suspension M9 cells. Vectors were then purified from
infected cells by Vivapure Adenopack 20 RT (Sartorius).
Exome and RNA sequencing. DNA and RNA library construction and NGS
tumor samples were performed at Center for Translational Genomics and Bioin-
formatics (CTGB)—San Raffaele Hospital, and at Genomix4Life S.r.l (Salerno).
Genomic DNA was fragmented and used for Illumina library construction. Exonic
regions were captured in solution using the Agilent mouse SureSelect All Exon kit
50Mb. Paired-end sequencing, resulting in 100 bp from each end of fragments, was
performed with the Hiseq2000 Genome Analyzer (Illumina) at target coverage of ×
120. RNA was fragmented and the sequencing library was prepared using Illumina
TruSeq mRNA stranded kit. Sequencing was performed with the Hiseq2000
Genome Analyzer (Illumina) at target depth of 60 mln of paired-end reads.
Germline sequences from the respective murine strain were downloaded from SRA
(experiment id: ERX391212) and used as control sample for comparison with
tumor. Quality control of sequenced reads was performed with FastQC 0.11.5.
Reads that aligned to more than one locus with the same mapping score were
filtered using Samtools 0.1.19. Somatic SNV were called by using mutect v1.1.17
and varscan2 v2.3.9 with default parameters, by explicitly comparing the tumor
sample vs the normal control sample. SNVs detected by at least one of the two
variant callers and inducing a missense amino-acid change were mapped on the
mm10 Refseq transcriptome by using Annovar. A 25-mer peptide was designed by
selecting the mutated amino acid plus 12 wild-type amido acids at both flanking
regions. MHC-I and MHC-II-binding predictions were performed by using the
consensus method of IEDB 2.17 software. Mutations were prioritized using
sequential filtering criteria with a funnel strategy. SNVs with predicted IC50 ≤ 500
nM for MHC-I and percentile rank score threshold ≤ 1 for MHC-II were selected.
SNVs with variant allele frequency in tumor ≥ 25% were further selected and finally
those expressed with at least one mutated read in RNAseq were retained.
In vivo tumor growth. For prophylactic experiments, 2 × 105 CT26 cells were s.c.
injected into the lower right flank, 2 weeks after immunization. For primary
metastases, 1 × 105 CT26 cells were injected i.v. into the tail vein 3 days before
vaccination. On day 16, lungs were perfused with India Ink 15%, harvested and
fixed in Fekete’s solution. Metastatic colonies on the surface of the lungs were
counted using a dissecting microscope. For established tumor setting experiments,
2 × 106 CT26 or 2 × 105 MC38 cells were s.c. injected as aforementioned. Before
treatments start (day 0), animals were randomized (tumor size average per group
70–100 mm3). Mice were killed as soon as signs of distress or a tumor volume
above 2000 mm3 occurred. Tumor growth was measured using digital caliper every
3–4 days. Tumor volume was calculated using the formula: 0.5 × length × width2,
where the length was the longer dimension.
In vivo treatments. Vaccines were administered via intramuscular injections in the
quadriceps by delivering a volume of 50 µl per side at 5 × 108 vp. For efficacy studies,
α-hPD-L1-mIgG1 (InvivoGgen, Cat. Number: hpdl1-mab9) and α-mPD1 (BioXcell,
clone RMP114, Cat. Number: BE0146) were administered twice a week until day 16
post treatment start. To deplete T-cell subsets, α -mCD8 (BioXcell, clone YTS169.4,
Cat. Number: BE0117) and α-mCD4 (BioXcell, clone YTS191, Cat. Number: BE0119)
were used. Each antibody was administered i.p. at a dosage of 200 μg.
Ex vivo immune analysis. IFN-γ ELISpot assays were performed on single-cell
suspensions of spleens. MSIP S4510 plates (Millipore, Billerica, MA) were coated
with 10 µg/ml of anti-mouse IFN-γ antibody (Cat. Number: CT317-C; U-CyTech)
and incubated overnight at 4 °C. After washing and blocking, mouse splenocytes
were plated in duplicate at two different cell densities and stimulated overnight
with single 25-mer peptides or peptide pool at a final concentration of 1 µg/ml. The
peptide diluent dimethyl sulfoxide (Sigma-Aldrich) and concanavalin A (Sigma-
Aldrich) were used, respectively, as negative and positive controls. Plates were
developed by subsequent incubations with biotinylated anti-mouse IFN-γ antibody
(dilution: 1/100; Cat. Number: CT317-D; U-CyTech), conjugated
streptavidin–alkaline phosphatase (dilution: 1/2500; Cat. Number 554065; BD
Biosciences) and finally with 5-bromo-4-chloro-3-indoyl-phosphate/nitro blue
tetrazolium 1-Step solution (Thermo Fisher Scientific). An automated enzyme-
linked immunosorbent–spot assay video analysis system automated plate reader
was used to analyze plates. ELISpot data were expressed as IFN-γ SFCs per million
splenocytes. ELISpot responses were considered positive if all the following con-
ditions occurred: (i) IFN-γ production present in ConA stimulated wells, (ii) the
number of spots seen in positive wells was three times the number detected in the
mock control wells (dimethyl sulfoxide), (iii) at least 30 specific spots/million
splenocytes. Intracellular IFN-γ staining was performed by ON stimulation of
splenocytes or isolated TIL with single peptides or peptide pools as antigen at final
concentration of 2 µg/ml for each peptide in presence of Golgi plug (catalog
555029, BD Biosciences). Dimethyl sulfoxide (catalog D2650, Sigma-Aldrich) was
used as negative control, and phorbolmyristate acetate/ionomycin (Sigma-Aldrich)
was used as positive controls. After overnight stimulation, cells were incubated with
purified anti-mouse CD16/CD32 (1 µg/106 cells; Cat. Number: 553142; BD Bios-
ciences) and then stained in FACS buffer (phosphate-buffered saline, 1% fetal calf
serum) with the following surface antibodies: allophycocyanin anti-mouse CD3e
(clone 145-2C11) (dilution: 1/100; Cat. Number: 553066); phycoerythrin anti-
mouse CD4 (clone RM4-5) (dilution: 1/100; Cat. Number: 553049) and PerCP
anti-mouse CD8a (clone 53–6.7) (dilution: 1/100; Cat. Number: 553036) (all from
BD Biosciences). Intracellular staining was performed after treatment with Cytofix/
Cytoperm (Cat. Number: 554722) and in the presence of PermWash (Cat. Number:
554723) (both from BD Biosciences) using fluorescein isothiocyanate anti-mouse
IFN-γ (clone XMG1.2) (dilution: 1/100; Cat. Number: 554411; BD Biosciences).
Stained cells were acquired on a FACS Canto flow cytometer and analyzed using
DIVA software (BD Biosciences). At least 20,000 CD8+, CD3+-gated events were
acquired for each sample.
Tumor biopsy for NGS and RNASeq. Tumors biopsies were collected from
treated mice and controls. After washing in RNA later, tumors were cut in pieces of
maximum 30mg, immediately flash-frozen in liquid nitrogen and stored at minus
80 °C until nucleic acid extraction. DNA and RNA extraction is performed by using
AllPrep DNA/RNA Mini Kit from QIAGEN, according to the manufacturer’s
instructions.
TILs preparation for IFN-γ ICS. Isolated tumors were first dissociated and
digested with collagenase I (Gibco) at 37 °C for 2 hours. Tumor homogenates were
depleted from erythrocytes using ACK lysing buffer (Gibco) and filtered through
70-µm cell strainers to generate single-cell suspensions. TIL were isolated from
tumor homogenates (Pan T cells isolation kit II, Miltenyi Biotec) and co-cultured
with APC from spleen of naive mice in presence of antigen stimuli.
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Gene expression analysis. Differentially expressed genes were estimated by
comparing treated versus untreated CT26 tumors using four different methods:
Deseq2, EdgeR, limma with Voom correction and NOISeq. A count matrix
reporting the number of reads mapping to each gene was determined by using the
Rsubread package and gene expression was expressed as Transcripts for Kilobase
million (TPM). Genes with <10 total count of mapped reads and expressed with a
TPM < 1 were excluded. The Benjamini–Hochberg correction was applied to the
list of differentially expressed genes identified by each method. Only genes iden-
tified by the consensus of three out of the four methods, with a difference of log2
FC of at least ±1 and a corrected p value ≤ 0.05 were retained.
Biological process enrichment analysis. Enrichment analysis was performed by
using the functional annotation chart tool included in DAVID web server using as
input the list of differentially expressed genes. Only the GO direct biological
processes significantly enriched with a p value ≤ 0.05 adjusted with Bonferroni
method were considered as significantly enriched. In total, 55 GO biological pro-
cesses resulted enriched by the genes modulated in tumors that respond to vaccine
and anti-PD1 compared with untreated.
TCR clonality analysis. T-cell receptor β-chain clonality was assessed from the
RNAseq data using the MiXCR tool applying the standard parameters reported in
the RNAseq workflow of the manual. Raw output of MiXCR (CDR3 sequences and
expression of the detected clonotypes) were further analyzed with the R package
tcR to obtain summary statistics. The expansion of T-cell clonotypes was deter-
mined by using the diversity evenness (DE50) defined as the minimum percentage
of unique CDR3 sequences needed to account for the 50% of sequencing reads
mapped on TCR genes.
Statistics. Statistical significance was determined by GraphPad Prism using the
nonparametric, two-tailed Mann–Whitney U test or as otherwise stated in the
figure legend.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The whole-exome sequencing and RNASeq data that support the finding of this study
have been deposited in Sequence Read Archive (SRA) under the accession code
PRJNA543001. All the other data of this study are available within the article and its
supplementary information files and from the corresponding author upon reasonable
request.
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